(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes studyRUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq ...

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack, Inc., a medical device company with a market capitalization of $1.78 million, has received a notification from the Nasdaq Stock Market indicating a potential delisting of its ...

Glucotrack, Inc., a medical device company with a market capitalization of $1.78 million, has received a notification from the Nasdaq Stock Market indicating a potential delisting of its securities ...

RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical device company with a market capitalization of $2.08 million, has announced a collaboration with OneTwo Analytics AB, a healthtech ...

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and ...